- Case report
- Open Access
- Open Peer Review
Nifedipine induced gingival enlargement in an edentulous patient: a case report with one year follow up
BMC Oral Healthvolume 18, Article number: 227 (2018)
Gingival enlargement due to calcium channel blockers is a common complaint reported by patients. It can be localized or generalized and can range from mild to severe, affecting patients appearance and function. Nifedipine induced gingival enlargement is noticed only in 10 % of patients and very few cases of Nifedipine induced gingival enlargement in an edentulous patient have been documented in the literature.
Here in, we report a case of gingival enlargement in a 70 year old hypertensive edentulous patient who was on low dose Nifedipine therapy. Patient wanted complete dentures. We planned to excise the overgrowth and followed up for 1 year.
Nifedipine induced gingival enlargement noticed only in 10 % of patients. Hence, there is a need for physicians and dentist to make a coordinated treatment plan and practice care while prescribing these drugs which are associated with gingival overgrowth.
Gingival hyperplasia is a multifactorial disease and drug induced gingival hyperplasia is an esthetically disfiguring over growth attributable to various medications [1, 2]. Calcium channel blockers (CCBs) are the most commonly prescribed anti-hypertensive drugs for patients with cardiovascular disorders. Gingival hyperplasia on long term use of Nifedipine is rare in the literature . The first documented case of Nifedipine induced gingival enlargement was reported in 1984 .Clinically-evident overgrowth of gingiva can be seen within 1–2 months after initiation of therapy. Incidence rate of nifedipine- induced gingival enlargement is 5–10% . Various factors attribute for overgrowth of gingiva, which include poor oral hygiene, genetic factors, individual susceptibility, and interaction between drugs and its metabolites with fibroblast of gingiva . Moreover age and gender have also been considered as risk factors for drug induced gingival enlargement [4, 7]. Nifedipine-induced gingival enlargement in an edentulous patient is rare in literature. Therefore, herein, we report a case of nifedipine-induced gingival enlargement in an edentulous patient.
A 70-year old male patient reported to clinic with a chief complaint of swollen gums of 5 year duration and wanted to replace his missing teeth. Patient noticed swollen gums prior to his 4 years of edentulous state and the condition persisted to present. He was a known hypertensive and was on medication for the same since 7 years (10 mg Nifedipine/day).On intraoral examination- pink, firm, irregular, nodular, non- tender enlargements were found on labial aspects of maxillary and mandibular residual alveolar ridges. The enlargements were asymptomatic in nature with no history of bleeding. Both arches were completely edentulous (Fig. 1). Panoramic radiograph showed no osseous deformities of maxilla and mandibular ridges (Fig. 2). Patient’s complete blood count, bleeding time, clotting time and platelet count were with in normal limits. An incisional biopsy was obtained from anterior right side of the maxilla. Histological report revealed hyperplastic and acantholytic stratified squamous epithelium with elongated rete ridges extending into connective tissue which was fibro collagenous and showed focal areas of fibrosis. Infiltration of chronic inflammatory cells and congested blood vessels were seen which suggested of gingival hyperplasia (Fig. 3). As patient wanted complete dentures, we planned to surgically excise entire overgrowth. Considering medical status of the patient, drug was not altered because, dose taken by the patient was low (10 mg/day). Local anesthesia devoid of vasoconstrictor was used to remove fibrous tissue from alveolar ridge with help of 15 no. B.P blade (Fig. 4). To avoid any discomfort during the early phase of wound healing, a surgical splint was placed on both ridges after thoroughly covering the operated site with periodontal dressing (Coe Pack). The patient was recalled and followed at a period of 1 week, 3 months, 6 months and 1 Year intervals (Figs. 5, 6, 7 and 8). No recurrence of growth was observed during any of the recall visits. After 3 months of surgery, patient had his complete dentures fabricated. Even on further recall visits there was no recurrence of growth noticed.
Discussion & conclusion
Nifedipine is a very potent and effective anti-hypertensive drug. However, long term use of these anti-hypertensive drugs causes gingival enlargement. In a community-based study, it was noticed that more than 6% of subjects taking Nifedipine had significant overgrowth and it was directly proportional to amount of gingival inflammation . As suggested by Seymour eat al  drug induced gingival hyperplasia is a multifactorial disease. Gingival enlargement in our case persisted even in edentulous state. It might be due to persistence of gingival overgrowth which did not resolve completely after extraction or might be due to incorporation of specific population of gingival fibroblast in alveolar ridge mucosa . The other reason for gingival enlargement in edentulous state can be due to defective collagen activity or due to decreased uptake of folic acid, blockage of aldosterone synthesis from adrenal cortex and an increase in adreno corticotropic hormone (ACTH) level and up regulation of keratinocyte growth factor . Drugs like Nifedipine, block influx of calcium ions thereby affecting homeostasis of collagen. Synthesis and degradation of collagen being altered leads to the abnormal growth .Also a link to androgen metabolism has been suggested. Evidence from animal studies confirms that, nifedipine when added to gingival fibroblast in culture, increase the conversion of testosterone to 5α dihydrotestosterone and this active metabolite would target subpopulations of fibroblasts [12, 13]. Idiopathic/Hereditary gingival enlargement from our case was ruled out as these enlargements are commonly detected at an early age and in few cases even at birth. Histological findings of present case suggested drug induced gingival enlargement. Genetic factors like Polymorphism of enzymes that are involved in transport (P-glycoprotein MDR1, CYP2C) and metabolism (cytochrome P450) of pharmacological active substances have been investigated in various studies. A relationship has been described between gingival enlargement and the expression of human leukocyte antigen (HLA; HLA-DR2-positive patients) . Other factors like heparin sulfate glycosaminoglycan (HSPG), basic fibroblast growth factor (bFGF), and transforming growth factor – beta (TGF-β) were found to be high in drug induced gingival enlargement . Dose of drug in present case was not altered as the dose was very low. Several studies in literature have suggested that a dose range of 30-60 mg/day is more associated with gingival enlargement . Dose of Nifedipine taken by patient was below the threshold limit of gingival overgrowth. Relation between gingival hyperplasia and pharmacokinetics of the drug has been investigated and are much debatable. This threshold might differ from patient to patient which might not be a suitable prognostic factors for gingival enlargement . Normal ridges were noticed after surgical excision in our patient. There was no recurrence of growth on a year follow up and on regular use of denture by our patient.
In conclusion, Nifedipine induced gingival enlargement is rare to occur in edentulous patients as there are no such reported cases from the past. The possible etiology for its occurrence is obsolete. Further studies are required to explain the association and existence of Nifedipine induced gingival enlargement in edentulous patients. Hence, there is a need for physicians and dentist to make a coordinated treatment plan and practice care while prescribing these drugs which are associated with gingival overgrowth.
Adreno corticotropic hormone
Basic fibroblast growth factor
Calcium channel blockers
Heparin sulfate glycosaminoglycan
Transforming growth factor – beta
Lu HK, Chou HP, Li CL, Wang MY, Wang LF. Stimulation of cells derived from nifedipine-induced gingival overgrowth with Porphyromonas gingivalis, lipopolysaccharide, and interleukin-1beta. J Dent Res. 2007;86:1100–4.
Karnik R, Bhat KM, Bhat GS. Prevalence of gingival overgrowth among elderly patients under amlodipine therapy at a large Indian teaching hospital. Gerodontology. 2012;29:209–13.
Kataoka M, Kido J, Shinohara Y, Nagata T. Drug-induced gingival overgrowth - a review. Biol Pharm Bull. 2005;28:1817–18121.
Lederman D, Lumerman H, Reuben S, Freedman PD. Gingival hyperplasia associated with Nifedipine therapy. Oral Surg Oral Med Oral Path. 1984;57:620–2.
Barak S, Engelberg IS, Hiss J. Gingival hyperplasia caused by nifedipine histopathologic findings. J Periodontol. 1987;58:639–42.
Barclay S, Thomason JM, Idle JR, Seymour RA. The incidence and severity of nifedipine induced gingival hyperplasia. J Clin Periodontol. 1992;19:311–4.
Miranda J, Brunet L, Roset P, Berrini L, Farre M, Mendieta. Prevalence and risk of gingival enlargement in patients treated with nifedipine. J Periodontol. 2001;72:605–11.
Seymour RA, Ellis JS, Thomason JM. Risk factors for drug –induced gingival enlargement. J Clin Periodontol. 2000;27:217–23.
Srivastava AK, Kundu D, Bandyopadhyay P, Pal AK. Management of amlodipine-induced gingival enlargement: series of three cases. J Indian Soc Periodontol. 2010;14:279–81.
Sunil PM, Nalluswami JS, Sanghar SJ, Joseph I. Nifedipine- induced gingival enlargement: correlation with dose and oral hygiene. J Pharm Bioallied Sci. 2012;4:191–3.
Dhingra K, Prakash S. Gingival overgrowth in partially edentulous ridges in an elderly female patient with epilepsy: a case report. Gerodontology. 2012;29:e1201–6.
Bharti V, Bansal C. Drug-induced gingival overgrowth: the nemesis of gingiva unravelled. J Indian Soc Periodontol. 2013;17:182–7.
Subramani T, Rathnavelu V, Yeap SK, Alitheen NB. Influence of mast cells in drug-induced gingival overgrowth. Mediat Inflamm. 2013;2013:275172.
Correa JD, Queiroz-Junior CM, Costa JE, Teixeira AL, Silva TA. Phenytoin-induced gingival overgrowth: a review of the molecular, immune, and inflammatory features. ISRN Dent. 2011;2011:497850.
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
Ethics approval and consent to participate
The protocol of this study was approved by institutional review board of Mamata Dental College (SRC/EH/2016–17/28). The treatment was considered to be standard without any experimental approach.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.